Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

IntelGenx Announces Dismissal of Patent Litigation Relating to Its Bupropion Hydrochloride Tablet

By Pharmaceutical Processing | February 3, 2011

IntelGenx Corp. today announced that the United States
District Court of Delaware has dismissed the lawsuit against IntelGenx that was
initiated by Biovail Laboratories International SLR in August 2009.

The dismissal of the litigation follows IntelGenx’ previous
announcement on January 4th, 2011 that the court had ruled in favor of
IntelGenx regarding claim construction for the two patent terms at issue in the
patent infringement action brought forward by Biovail under the Drug Price
Competition and Patent Term Restoration Act (“Hatch-Waxman Act”). The
ruling arose from a special proceeding required under U.S. patent law
called a “Markman Hearing” where both sides presented to the court
their arguments on how they believed the patent terms at issue should be
interpreted. Subsequent to the ruling on the Markman Hearing, Biovail agreed to
dismissal of the action.

“The litigation was a major obstacle in our partnership
discussions for CPI-300, so we are delighted to have this legal process behind
us,” commented Horst Zerbe, President and CEO of IntelGenx. “We are
in the final steps of accumulating the data necessary to address FDA’s questions
from the Complete Response Letter and submit our response to the Agency in the
coming months.”

 

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards